3,843 Shares in Astrazeneca Plc $AZN Bought by Savvy Advisors Inc.
by Sarita Garza · The Markets DailySavvy Advisors Inc. purchased a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,843 shares of the company’s stock, valued at approximately $353,000.
Several other institutional investors have also bought and sold shares of the stock. Binnacle Investments Inc grew its holdings in Astrazeneca by 21.8% during the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after buying an additional 118 shares in the last quarter. Chapin Davis Inc. grew its holdings in Astrazeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares in the last quarter. 44 Wealth Management LLC grew its holdings in Astrazeneca by 0.7% during the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock worth $1,283,000 after buying an additional 124 shares in the last quarter. CoreCap Advisors LLC grew its holdings in Astrazeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after buying an additional 125 shares in the last quarter. Finally, Highline Wealth Partners LLC grew its holdings in Astrazeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after buying an additional 129 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Citigroup started coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Weiss Ratings started coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $95.75.
Astrazeneca Trading Up 0.3%
AZN stock opened at $204.90 on Friday. The firm has a market cap of $317.79 billion, a PE ratio of 35.30, a PEG ratio of 1.54 and a beta of 0.35. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a fifty-two week low of $126.16 and a fifty-two week high of $212.71.
Astrazeneca Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were issued a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 74.83%.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.